2023-05-06 13:34:03
In April 2021, the Geneva biotech GeNeuro sparked increased interest following the detection in some covid patients of a protein on which the company has been working for years to design a treatment for multiple sclerosis (MS). The course of the company founded in 2006 has soared. Today, the situation has settled down, but GeNeuro continues its work on the search for a treatment once morest the effects of long covid.
1683382404
#long #covid #clear #ground #machetes
